Ortho Clinical Diagnostics has received the CE mark for its next-generation Vitros high sensitivity troponin I assay. A press release reports that this new assay is the latest addition to the company’s robust cardiology menu and is a critical tool for clinicians who are seeking improved strategies to more rapidly and accurately identify patients suffering from a heart attack. It adds that the assay also aids in identifying low-risk patients who may be safely discharged to help reduce the cost of care and alleviate the burden on hospital resources.
The Vitros high sensitivity troponin I assay can run on Ortho’s latest analyser, the Vitros XT 7600 integrated system, as well as the Vitros ECi/ECiQ immunodiagnostic systems, the Vitros 3600 immunodiagnostic system and the Vitros 5600 integrated system.
Heidi Casaletto, head of portfolio strategy and marketing at Ortho, comments: “We are proud to bring the Vitros high sensitivity troponin I assay to market in providing hospitals with more reliable and precise diagnostics for cardiac care. Improved analytical performance complies with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) definition of high sensitivity, enabling use with rapid rule-in/rule-out diagnostic protocols and allowing hospitals to more quickly diagnose and treat patients.”
The VITROS High Sensitivity Troponin I assay is available commercially in all countries that accept CE Mark, including Chile and Australia.